Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences' Shares Recover after CMS Agrees to Correct Published Reimbursement Level for Cologuard

NEW YORK (GenomeWeb) – Shares of Exact Sciences rebounded today following a statement from the company that the Centers for Medicare and Medicaid Services had made an error in the 2015 clinical lab fee schedule for the firm's Cologuard test.

On Friday, CMS released the lab fee schedule, which establishes reimbursement rates for various diagnostic tests. According to the schedule, CMS set the National Reimbursement Limit code for G0464, which is assigned to the Cologuard colorectal cancer screening test, at $364.61, below the $502 reimbursement level that CMS had said in November that it would pay for the test.

The new rate resulted in a sell-off of Exact Science's stock and a 5 percent decline in its shares on Friday.

Later that day, however, the Madison, Wis.-based firm said that CMS had informed it that the agency will issue a correction to the 2015 lab fee schedule this week, and CMS would reimburse $500.76 for Cologuard, based on the national limit for CPT codes 82274, 81275, and 81315.

In afternoon trading shares of Exact Sciences rose about 6 percent at $27.50 on the Nasdaq and were up as much as 8 percent.

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.